文献速递免疫规划传染病防控与疫情报告

腺病毒载体与蛋白纳米颗粒异源初免-加强接种诱导针对中东呼吸综合征冠状病毒的Th1和Th2应答

Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.
PubMed 文献 · Vaccine · 2018-05-05

本研究开发了编码中东呼吸综合征冠状病毒(MERS-CoV)刺突基因的重组腺病毒5型(Ad5/MERS)和铝佐剂刺突蛋白纳米颗粒两种疫苗,在小鼠中比较异源初免-加强(Ad5/MERS初免、蛋白纳米颗粒加强及反之)与同源初免-加强方案的免疫应答。结果显示异源方案和同源蛋白纳米颗粒方案诱导中和抗体,含Ad5/MERS方案诱导Th1活化,异源方案同时诱导Th1和Th2应答,两种方案均提供攻毒保护。

要点

  • 异源初免-加强和同源刺突蛋白纳米颗粒接种诱导MERS-CoV中和抗体。
  • 含Ad5/MERS的免疫方案诱导Th1细胞活化,仅蛋白纳米颗粒方案不诱导。
  • 异源初免-加强方案同时诱导Th1和Th2应答,同源方案未同时诱导。

核心结论

  • 以Ad5/MERS初免、刺突蛋白纳米颗粒加强的异源免疫可能是预防MERS-CoV感染的有效策略。

研究设计与样本

  • 研究开发了编码MERS-CoV刺突基因的重组腺病毒5型(Ad5/MERS)和铝佐剂刺突蛋白纳米颗粒两种疫苗,在小鼠中比较异源初免-加强(Ad5/MERS初免、蛋白纳米颗粒加强及反之)与同源初免-加强(刺突蛋白纳米颗粒或Ad5/MERS初免和加强)的免疫应答。

主要发现

  • 两种疫苗均诱导针对MERS-CoV的特异性免疫球蛋白G。
  • 中和抗体仅由异源初免-加强免疫和刺突蛋白纳米颗粒同源免疫诱导。
  • Th1细胞活化由含Ad5/MERS的免疫方案诱导,仅含刺突蛋白纳米颗粒的方案未诱导。
  • 含Ad5/MERS的异源初免-加强方案同时诱导Th1和Th2应答,同源初免-加强方案未同时诱导。
  • 异源初免-加强和同源刺突蛋白纳米颗粒接种均能提供小鼠对MERS-CoV攻毒的保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic and zoonotic virus with a fatality rate in humans of over 35%. Although several vaccine candidates have been developed, there is still no clinically available vaccine for MERS-CoV. In this study, we developed two types of MERS-CoV vaccines: a recombinant adenovirus serotype 5 encoding the MERS-CoV spike gene (Ad5/MERS) and spike protein nanoparticles formulated with aluminum (alum) adjuvant. Next, we tested a heterologous prime-boost vaccine strategy, which compared priming with Ad5/MERS and boosting with spike protein nanoparticles and vice versa, with homologous prime-boost vaccination comprising priming and boosting with either spike protein nanoparticles or Ad5/MERS. Although both types of vaccine could induce specific immunoglobulin G against MERS-CoV, neutralizing antibodies against MERS-CoV were induced only by heterologous prime-boost immunization and homologous immunization with spike protein nanoparticles. Interestingly, Th1 cell activation was induced by immunization schedules including Ad5/MERS, but not by those including only spike protein nanoparticles. Heterologous prime-boost vaccination regimens including Ad5/MERS elicited simultaneous Th1 and Th2 responses, but homologous prime-boost regimens did not. Thus, heterologous prime-boost may induce longer-lasting immune responses against MERS-CoV because of an appropriate balance of Th1/Th2 responses. However, both heterologous prime-boost and homologous spike protein nanoparticles vaccinations could provide protection from MERS-CoV challenge in mice. Our results demonstrate that heterologous immunization by priming with Ad5/MERS and boosting with spike protein nanoparticles could be an efficient prophylactic strategy against MERS-CoV infection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Jung SY, Kang KW, Lee EY, et al. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. Vaccine. 2018. PMID: 29739720. doi:10.1016/j.vaccine.2018.04.082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。